Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 01, 2016 07:00 ET | Source: Larimar Therapeutics, Inc.

Zafgen to Present at the Cowen & Company 36th Annual Health Care Conference

BOSTON, March 01, 2016 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and...
February 29, 2016 07:00 ET | Source: Larimar Therapeutics, Inc.

Zafgen Joins NORD in Raising Awareness of Rare Disease Day

BOSTON, Feb. 29, 2016 (GLOBE NEWSWIRE) -- Zafgen Inc., a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex...
February 18, 2016 06:30 ET | Source: Larimar Therapeutics, Inc.

Zafgen's Phase 2b Trial of Beloranib in Severe Obesity Complicated by Type 2 Diabetes Achieves Primary Efficacy Endpoint

- Beloranib demonstrates statistically and clinically significant improvements in body weight and glycemic control over six months of randomized treatment –-Conference call scheduled for 8:30 AM...
February 16, 2016 16:05 ET | Source: Larimar Therapeutics, Inc.

Zafgen to Participate in Upcoming Investor Conferences

BOSTON, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and...
February 02, 2016 07:00 ET | Source: Larimar Therapeutics, Inc.

Zafgen to Present at Upcoming Investor Conferences

BOSTON, Feb. 02, 2016 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and...
January 20, 2016 06:00 ET | Source: Larimar Therapeutics, Inc.

Zafgen's Pivotal Phase 3 Trial of Beloranib in Prader-Willi Syndrome Achieves Co-Primary Efficacy Endpoints

- bestPWS Study is the first Phase 3 pivotal trial to show significant weight-loss and improve hyperphagia-related behaviors in PWS patients- -Statistically significant at both 2.4 mg and 1.8 mg...
December 02, 2015 19:24 ET | Source: Larimar Therapeutics, Inc.

Zafgen Announces Beloranib IND Placed on Complete Clinical Hold

BOSTON, Dec. 02, 2015 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and...
December 02, 2015 06:30 ET | Source: Larimar Therapeutics, Inc.

Zafgen Provides Clinical Update on Beloranib

BOSTON, Dec. 02, 2015 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and...
November 10, 2015 16:01 ET | Source: Larimar Therapeutics, Inc.

Zafgen Announces Third Quarter 2015 Financial Results

Company to Host Conference Call at 4:30 PM Eastern Time to Review Progress with Beloranib Program Ends Quarter with Cash, Cash Equivalents and Marketable Securities of $204 Million; Increases...
November 03, 2015 16:01 ET | Source: Larimar Therapeutics, Inc.

Zafgen to Host Conference Call to Discuss Third Quarter 2015 Financial Results

BOSTON, Nov. 03, 2015 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and...